Quantitative PET Imaging in Drug Development: Estimation of Target Occupancy

被引:0
|
作者
Mika Naganawa
Jean-Dominique Gallezot
Samantha Rossano
Richard E. Carson
机构
[1] Yale University,PET Center, Department of Radiology and Biomedical Imaging
[2] Yale University,Department of Biomedical Engineering
来源
关键词
Target Occupancy; Receptor Occupancy Studies; Occupancy Plot (OCCPLOT); Naganawa; Occupancy Estimates;
D O I
暂无
中图分类号
学科分类号
摘要
Positron emission tomography, an imaging tool using radiolabeled tracers in humans and preclinical species, has been widely used in recent years in drug development, particularly in the central nervous system. One important goal of PET in drug development is assessing the occupancy of various molecular targets (e.g., receptors, transporters, enzymes) by exogenous drugs. The current linear mathematical approaches used to determine occupancy using PET imaging experiments are presented. These algorithms use results from multiple regions with different target content in two scans, a baseline (pre-drug) scan and a post-drug scan. New mathematical estimation approaches to determine target occupancy, using maximum likelihood, are presented. A major challenge in these methods is the proper definition of the covariance matrix of the regional binding measures, accounting for different variance of the individual regional measures and their nonzero covariance, factors that have been ignored by conventional methods. The novel methods are compared to standard methods using simulation and real human occupancy data. The simulation data showed the expected reduction in variance and bias using the proper maximum likelihood methods, when the assumptions of the estimation method matched those in simulation. Between-method differences for data from human occupancy studies were less obvious, in part due to small dataset sizes. These maximum likelihood methods form the basis for development of improved PET covariance models, in order to minimize bias and variance in PET occupancy studies.
引用
收藏
页码:3508 / 3541
页数:33
相关论文
共 50 条
  • [31] The application of positron emission tomography (PET) imaging in CNS drug development
    Suridjan, Ivonne
    Comley, Robert A.
    Rabiner, Eugenii A.
    [J]. BRAIN IMAGING AND BEHAVIOR, 2019, 13 (02) : 354 - 365
  • [32] PET IN DRUG DEVELOPMENT
    Lammertsma, Adriaan A.
    [J]. 2012 9TH IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING (ISBI), 2012, : 910 - 910
  • [33] The application of positron emission tomography (PET) imaging in CNS drug development
    Ivonne Suridjan
    Robert A. Comley
    Eugenii A Rabiner
    [J]. Brain Imaging and Behavior, 2019, 13 : 354 - 365
  • [34] Designing drug occupancy studies with PET neuroimaging: Sample size, occupancy ranges and analytical methods
    Laurell, Gjertrud Louise
    Plaven-Sigray, Pontus
    Svarer, Claus
    Ogden, R. Todd
    Knudsen, Gitte Moos
    Schain, Martin
    [J]. NEUROIMAGE, 2022, 263
  • [35] PET Molecular Imaging for Precision Cancer Medicine and Efficient Drug Development
    Watanabe, Yasuyoshi
    [J]. CANCER SCIENCE, 2018, 109 : 555 - 555
  • [36] Designing drug occupancy studies with PET neuroimaging: Sample size, occupancy ranges and analytical methods
    Laurell, G.
    Plaven-Sigray, P.
    Svarer, C.
    Ogden, R.
    Knudsen, G.
    Schain, M.
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2022, 42 (1_SUPPL): : 126 - 127
  • [37] PET for drug development
    Halldin, C
    Gulyás, B
    Farde, L
    [J]. FROM MORPHOLOGICAL IMAGING TO MOLECULAR TARGETING: IMPLICATIONS TO PRECLINICAL DEVELOPMENT, 2004, 48 : 95 - 109
  • [38] Dual respiratory and cardiac motion estimation in PET imaging: Methods design and quantitative evaluation
    Feng, Tao
    Wang, Jizhe
    Tsui, Benjamin M. W.
    [J]. MEDICAL PHYSICS, 2018, 45 (04) : 1481 - 1490
  • [39] Predicting transporter-based drug disposition using quantitative proteomics and pet imaging
    Unadkat, Jashvant
    [J]. DRUG METABOLISM REVIEWS, 2016, 48 : 10 - 10